Financial Performance (Quarter Ended June 30, 2026)

Income Statement Highlights (₹ in lakhs):

  • Revenue from operations: ₹3,787.42 (compared to ₹2,860.46 in Q1 FY2026)
  • Other income: ₹88.69 (compared to ₹17.12 in Q1 FY2026)
  • Total income: ₹3,876.11 (compared to ₹2,877.58 in Q1 FY2026)
  • Cost of materials consumed: ₹1,213.50
  • Employee benefit expense: ₹367.79
  • Finance cost: ₹11.79
  • Depreciation & amortization: ₹87.99
  • Other expenditure: ₹574.35
  • Profit before tax: ₹1,790.08 (compared to ₹1,065.67 in Q1 FY2026)
  • Tax expense: ₹461.92 (Current tax: ₹457.68, Deferred tax: ₹4.24)
  • Net profit for the period: ₹1,328.16 (compared to ₹794.13 in Q1 FY2026)
  • Total comprehensive income: ₹1,329.59

Key Metrics:

  • Earnings per share (EPS): ₹4.24 (basic and diluted, not annualized)
  • Paid-up equity share capital: ₹3,135.79 lakhs (face value ₹10 each)
  • Reserves (excluding revaluation) as of previous year: ₹12,551.43 lakhs

Comparative Performance

Quarter-over-Quarter Comparison (Q1 FY2027 vs Q4 FY2026):

  • Revenue increased marginally from ₹3,777.45 to ₹3,787.42
  • Net profit increased significantly from ₹851.84 to ₹1,328.16
  • EPS increased from ₹2.72 to ₹4.24

Year-over-Year Comparison (Q1 FY2027 vs Q1 FY2026):

  • Revenue increased by 32.4% from ₹2,860.46 to ₹3,787.42
  • Net profit increased by 67.2% from ₹794.13 to ₹1,328.16
  • EPS increased from ₹2.53 to ₹4.24

Approval and Review Process

  • The financial results were reviewed by the audit committee and approved by the board of directors at their meeting held on August 11, 2026
  • The statutory auditors, J.T. Shah & Co., conducted a limited review and issued an unqualified report
  • The results were prepared in accordance with Indian Accounting Standards (Ind AS)

Additional Information

  • The company has only one reportable segment: "Pharma Polymers"
  • No exceptional items were reported during the quarter
  • The company does not have any subsidiaries, associates, or joint ventures as of June 30, 2026
  • Figures for previous periods have been regrouped/reclassified where necessary for comparability
  • The quarter ended March 31, 2026 figures are derived from audited annual figures and unaudited published year-to-date figures